Patrick Hwu highlights 2025 study by Jonathan Zager on Melphalan hepatic perfusion for metastatic uveal melanoma
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared an article by Jonathan S. Zager et al. on X, adding:
“Exciting multi-institutional study led Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with metastatic uveal melanoma.
Congrats to Jonathan Zager and colleagues!”
Read more about the study on the Moffitt Cancer Center website.
Title: An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Journal: Annals of Surgical Oncology
Authors: Jonathan S. Zager, Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J. Eschelman, Evan S. Glazer, Aslam Ejaz, J. Harrison Howard, Erika Richtig, Sebastian Ochsenreither, Sunil A. Reddy, Michael C. Lowe, Georgia M. Beasley, Anja Gesierich, Armin Bender, Martin Gschnell, Reinhard Dummer, Michel Rivoire, Ana Arance, Stephen William Fenwick, Joseph J. Sacco, Sebastian Haferkamp, Carsten Weishaupt, Johnny John, Matthew Wheater, Christian H. Ottensmeier
More posts featuring uveal melanoma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023